Alvotech SA

Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines through its subsidiaries. The firm's pipeline contains biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. The company was founded on August 23, 2021 and is headquartered in Luxembourg.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alvotech reports robust Q1 earnings, eyes biosimilar market leadership

Alvotech's Q1 2024 earnings call highlighted strong financial performance, progress in commercializing biosimilars, and a positive outlook for revenue growth in 2024. The company's focus on interchangeability, exclusive agreements, and expanding its product pipeline positions it well for future success in the biosimilars market.

Alvotech reports stellar revenue growth and strategic financing moves

Alvotech's strong financial performance, focus on biosimilars, and strategic financing decisions underscore its growth trajectory. Challenges in maintaining margins and meeting EBITDA targets exist, but opportunities from new applications and revenue mix diversification are promising.

Alvotech reports robust Q3 earnings, eyes growth amid profitability challenges

Alvotech's Q3 2024 earnings call showcased strong financial performance, with total revenues reaching $339 million for the first 9 months.
The company reported positive operating profit and adjusted EBITDA for the second consecutive quarter, driven by product revenue growth and margin improvement.
Guidance for 2024 revenue remains at $400 million to $500 million, with a focus on operational execution and maximizing launches for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer

Alvotech Announces Changes to its Leadership Team

Alvotech S.A. (“Alvotech”) has submitted its application to Nasdaq Iceland for admission of its shares for trading on the Nasdaq Iceland Main Market under the ticker symbol “ALVO”. The application awaits approval from Nasdaq Iceland.

Alvotech Submits its Application for Admission of the Company's Shares to Trading on Nasdaq Iceland Main Market

Alvotech (NASDAQ:ALVO ) Q3 2022 Earnings Conference Call November 16, 2022 8:00 AM ET Company Participants Benedikt Stefansson - Director of Investor Relations and Global Communication Robert Wessman - Executive Chairman & Founder Anil Okay - Chief Commercial Officer Mark Levick - Chief Executive Officer Joel Morales - Chief Financial Officer Conference Call Participants Mark Bavoso - Morgan Stanley Andrew Baum - Citi Carl Byrnes - Northland Capital Markets Ash Verma - UBS Operator Good day, and thank you for standing by. Welcome to the Alvotech Third Quarter 2022 Earnings Conference Call.

Alvotech (ALVO) Q3 2022 Earnings Call Transcript

Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investors

Alvotech Secures Financing Facilities of Approximately $136 Million

REYKJAVIK, Iceland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of 2022 and provided a summary of recent corporate highlights.

Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update

Reykjavik, Iceland and Mumbai, India (November 14, 2022) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today that the Therapeutic Goods Administration of Australia has granted marketing authorization to Cipla Australia Pty Ltd (“Cipla”) for Alvotech's AVT02, a high-concentration low-volume biosimilar to Humira® (adalimumab).

Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02

Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2022, after U.S. markets close on Tuesday, November 15, 2022.

Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022

REYKJAVIK, Iceland , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in the Jefferies London Healthcare Conference from November 15th to November 17th.

Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November

Expanded partnership covers biosimilar candidates in immunology and oncology

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

REYKJAVIK, Iceland, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner Fuji Pharma Co., Ltd. (“Fuji”) has submitted an application to the Japanese Ministry of Health, Labor and Welfare for marketing approval of the first biosimilar candidate developed under the companies' exclusive commercialization partnership.

Alvotech's Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corporate leadership team as Chief Quality Officer, effective October 14.  Ms. Tanksley succeeds Reem Malki, who is stepping down for personal reasons.

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

REYKJAVIK ICELAND; BAD VILBEL, GERMANY (September 22, 2022) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and STADA Arzneimittel AG (STADA), announced today the launch of Hukyndra®, a high-concentration, low-volume, citrate-free formulation, biosimilar to Humira® (adalimumab), in Switzerland.

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication from the U.S. Food and Drug Administration (FDA) detailing its assessment of the March 2022 inspection of Alvotech's manufacturing facility in Reykjavik, Iceland and Alvotech's subsequent written responses to the FDA.

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech (NASDAQ:ALVO ) Q2 2022 Earnings Conference Call September 1, 2022 8:00 AM ET Company Participants Benedict Stephan - Investor Relations Robert Wessman - Executive Chairman & Founder Mark Levick - Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategic Officer Conference Call Participants Tybalt Mornan - Morgan Stanley Karen Marchetti - Northland Jason Guerra - Bank of America Benedict Stephan [Call Started Abruptly] materials and some of our statements that we make today may include forward looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission, and the Nasdaq Iceland Stock Exchange.

Alvotech (ALVO) Q2 2022 Earnings Call Transcript

REYKJAVIK, Iceland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first half of 2022 and provided a summary of recent corporate highlights. The company also filed the interim financial statements with the Icelandic stock exchange for the first six months of 2022, in accordance with the Nasdaq First North rulebook.

Alvotech Reports First Half 2022 Financial Results and Business Update

Alvotech releases ESG indicators covering both 2020 and 2021

Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021

REYKJAVIK, Iceland, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®. The objective of the study is to demonstrate clinical similarity of AVT03 to Prolia® in terms of efficacy, safety, immunogenicity, and pharmacokinetics in postmenopausal women with osteoporosis. The results from this trial will be used to support additional indications for AVT03 to XGeva® based on extrapolation.

Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in two upcoming investor conferences in September 2022. Representatives of Alvotech will hold two fireside chats:

Alvotech to Participate in Two Upcoming Investor Conferences in September 2022

REYKJAVIK, Iceland, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months and second quarter of 2022, after U.S. markets close on Wednesday, August 31, 2022.

Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its Board of Directors has approved a plan to move its share listing from the First North Growth Market to the Nasdaq Main Market in Iceland (“Main Market”). Alvotech's admission to trading on the Main Market is subject to an extensive application process. A Main Market listing can increase a company's visibility and may result in inclusion in Icelandic and international indexes. Starting in September 2022, shares of companies listed on the Icelandic Main Market may become eligible for the FTSE Global All Cap and related indexes, subject to meeting certain conditions with respect to trading volume and duration of listing. The selection of shares to be included in the FTSE indexes is revised periodically, every six months.

Alvotech's Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

MORRISTOWN, N.J.--(BUSINESS WIRE)--Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the company's proposed generic to Xifaxan®, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults. “We are extremely pleased with the district court's decision, which brings us one step closer to bringing a more affordable alternative t

Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company's Proposed Generic to Xifaxan® for IBS-D

Alvotech (ALVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Alvotech (ALVO), Here's Why It's a 'Buy' Now

The mean of analysts' price targets for Alvotech (ALVO) points to an 119.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Alvotech (ALVO) Could Surge 119%: Read This Before Placing a Bet

REYKJAVIK, Iceland, July 20, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®. The clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia® in healthy adult male subjects.

News for Alvotech SA Stock (ALVO)